>>Signaling Pathways>> Metabolism>> Sterol Biosynthesis>>Pitavastatin lactone-d4

Pitavastatin lactone-d4

Catalog No.GC49340

An internal standard for the quantification of pitavastatin lactone

Products are for research use only. Not for human use. We do not sell to patients.

Pitavastatin lactone-d4 Chemical Structure

Cas No.: N/A

Size 가격 재고 수량
500 µg
US$341.00
재고 있음
1 mg
US$613.00
재고 있음
5 mg
US$1,704.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Pitavastatin lactone-d4 is intended for use as an internal standard for the quantification of pitavastatin lactone by GC- or LC-MS. Pitavastatin lactone is a major phase 2 metabolite of the HMG-CoA reductase inhibitor pitavastatin .1,2 Pitavastatin lactone is formed when pitavastatin undergoes glucuronidation by the UDP-glucuronysyltransferase (UGT) isoforms UGT1A1, UGT1A3, or UGT2B7 to form pitavastatin glucuronide, which then undergoes non-enzymatic conversion to pitavastatin lactone. It can be retroconverted to pitavastatin via hydrolysis.

1.Fujino, H., Yamada, I., Shimada, S., et al.Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonizationXenobiotica33(1)27-41(2003) 2.Aoki, T., Nishimura, H., Nakagawa, S., et al.Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductaseArzneimittelforschung47(8)904-909(1997)

리뷰

Review for Pitavastatin lactone-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pitavastatin lactone-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.